43.43
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$43.58
Offen:
$42.87
24-Stunden-Volumen:
621.70K
Relative Volume:
0.76
Marktkapitalisierung:
$4.00B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-6.7125
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
-4.28%
1M Leistung:
+3.23%
6M Leistung:
-14.68%
1J Leistung:
-7.08%
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RARE
Ultragenyx Pharmaceutical Inc
|
43.43 | 4.00B | 522.75M | -558.99M | -439.53M | -6.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
453.20 | 116.71B | 11.02B | -535.60M | -1.35B | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
663.86 | 72.58B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
649.09 | 39.44B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
265.96 | 34.30B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
111.89 | 26.82B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
2021-08-19 | Eingeleitet | UBS | Sell |
2021-07-15 | Eingeleitet | Guggenheim | Neutral |
2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
2021-03-02 | Fortgesetzt | Stifel | Buy |
2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
2019-08-02 | Fortgesetzt | Wedbush | Outperform |
2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2019-02-22 | Fortgesetzt | Raymond James | Outperform |
2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
2018-05-10 | Eingeleitet | Goldman | Neutral |
2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
2018-02-21 | Bestätigt | Stifel | Buy |
2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
2017-12-05 | Bestätigt | Barclays | Equal Weight |
2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
WCM Investment Management LLC Has $5.73 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by abrdn plc - MarketBeat
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study - MSN
Ultragenyx Pharmaceuticals: Buy Rating Supported by Promising Gene Therapy Trial Results and Regulatory Advancements - TipRanks
Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $92.43 - MarketBeat
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update - GlobeNewswire
Rare Disease Leader Ultragenyx to Reveal Full Year Performance: Key Earnings Date Announced - StockTitan
UX111 offers cognitive, motor skill gains in Sanfilippo syndrome type A - Sanfilippo News
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Adicet's T-Cell Therapy ADI-100 Fast Tracked by FDA for Refractory Systemic Lupus Erythematosus - CGTLive™
Ultragenyx announces new data on UX111 AV gene therapy - Yahoo Finance
Ultragenyx updates on UX111 AAV gene therapy - The Pharma Letter
Ultragenyx links cognitive improvement to biomarker in latest Sanfilippo gene therapy readout - FirstWord Pharma
Ultragenyx Announces New Data Demonstrating that Treatment - GlobeNewswire
Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2 - Marketscreener.com
Ultragenyx reports positive data on gene therapy for rare disease - MSN
Ultragenyx reports positive data on gene therapy for rare disease By Investing.com - Investing.com South Africa
Breakthrough: Ultragenyx's Gene Therapy Reverses Cognitive Decline in Fatal Childhood Disease - StockTitan
KBC Group NV Buys 58,442 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart
Ultragenyx Pharmaceutical: Advancing On Multiple Fronts (NASDAQ:RARE) - Seeking Alpha
Wilson’s Disease Market Expected to rise, 2034 | Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, expected to drive market - Barchart
Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications - CGTLive™
Learn to Evaluate (RARE) using the Charts - Stock Traders Daily
Ultragenyx Pharmaceutical (NASDAQ:RARE) adds US$374m to market cap in the past 7 days, though investors from three years ago are still down 37% - Simply Wall St
What is Wedbush’s Estimate for RARE FY2024 Earnings? - Defense World
Wedbush Has Positive Outlook for RARE FY2027 Earnings - Defense World
Wedbush Equities Analysts Boost Earnings Estimates for RARE - MarketBeat
Ultragenyx's SWOT analysis: rare disease stock poised for growth - Investing.com India
Cantor Fitzgerald Forecasts RARE FY2025 Earnings - Defense World
FY2024 Earnings Estimate for RARE Issued By Leerink Partnrs - Defense World
Mucopolysaccharidosis (MPS) Treatment Market Growth in Future - openPR
Ultragenyx's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Australia
Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views - Benzinga
Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Leerink Partnrs Has Positive Outlook of RARE FY2024 Earnings - MarketBeat
Cantor Fitzgerald Predicts RARE FY2025 Earnings - MarketBeat
Assenagon Asset Management S.A. Sells 76,160 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Assenagon Asset Management S.A. Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):